Is adagrasib a targeted drug or a chemotherapy drug?

Adagrasib is a targeted drug rather than a traditional chemotherapy drug. It belongs to a class of new anti-tumor drugs called KRAS G12C inhibitors, which are mainly used to treat tumors related to KRAS G12C mutations, especially advanced non-small cell lung cancer (NSCLC). Compared with chemotherapy drugs, adagrasib has a more specific mechanism of action and lower toxic and side effects.

Targeted drugs inhibit the growth and spread of tumors by interfering with specific biological pathways or proteins in tumor cells while minimizing damage to normal cells. Adagarasib inhibits the growth and proliferation of tumor cells by targeting the KRAS G12Cmutated protein, which is part of the RAS signaling pathway. This targeted effect makes adagrasib more effective in inhibiting tumor growth while reducing its adverse effects on normal cells.

In contrast, traditional chemotherapy drugs usually treat cancer by killing rapidly proliferating cells, but this can also affect the rapid division of normal cells, leading to a series of toxic side effects, such as nausea, vomiting, hair loss, etc. In contrast, adagrasib, as a targeted drug, acts more precisely on tumor cells, so its toxic and side effects are relatively low.

In general, adagrasib, as a targeted drug, provides a more precise and effective treatment option for the treatment of KRAS G12C mutation-related tumors. It has less toxic side effects than chemotherapy drugs, allowing patients to better tolerate treatment and improve quality of life.